重症成人高流量鼻导管撤机策略:一项随机临床试验
本研究为多中心随机对照试验(SLOWH试验),纳入ICU中接受HFNC后符合撤机标准的成人(≥18岁),随机分为先降流量(FR)、先降FiO2(OR)或同步降低(SR)三组。主要终点为HFNC撤机成功率(过渡至常规氧疗后24小时内无需重新应用HFNC、无创通气或气管插管)。87例完成试验,FR组成功率94%、OR组81%、SR组77%(p=0.15),中位撤机时长三组分别为31.0、29.5、29.5小时(p=0.87),均无统计学显著差异。
要点
- 在符合HFNC撤机标准的ICU成人中,先降流量组撤机成功率为94%(31例中),先降FiO2组为81%(26例中),同步降低组为77%(30例中),组间p=0.15。
- 三组中位撤机时长分别为FR组31.0小时(IQR 29.0-45.8)、OR组29.5小时(IQR 28.0-60.4)、SR组29.5小时(IQR 26.5-45.0),p=0.87无显著差异。
- 撤机成功定义为过渡至常规氧疗后24小时内无需重新应用HFNC、无创通气或气管插管。
- 本研究样本量较小(87例完成),三种撤机策略的选择暂无显著预后差异证据支持。
适用人群与场景
- ICU中接受HFNC治疗并符合撤机标准的成人(≥18岁)。
- 来自三家三级医院,共102例筛选,排除15例后87例完成试验。
诊断标准与关键阈值
- 撤机成功定义:过渡至常规氧疗后24小时内无需重新应用HFNC、无创通气或气管插管。
- 撤机标准:原文提及「符合撤机标准」,但未列出具体标准条件。
处置流程与药物剂量
- 三种撤机策略:先降流量(FR)、先降FiO2(OR)、同步降低(SR);原文未提供具体降低速率、目标值或操作细节。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要终点撤机成功率:FR组94%、OR组81%、SR组77%,p=0.15,无统计学显著差异。
- 中位撤机时长:FR组31.0小时(IQR 29.0-45.8)、OR组29.5小时(IQR 28.0-60.4)、SR组29.5小时(IQR 26.5-45.0),p=0.87,无显著差异。
证据类型、等级与局限
- 随机对照试验(RCT),多中心,样本量较小(87例完成),原文未报告证据等级或推荐强度。
- 局限:样本量小,可能不足以检测组间差异;原文未报告盲法细节(随机化由独立统计师生成的随机数字序列,研究者和参与者盲态)。
对床旁实践的改变
- 对于符合撤机标准的HFNC成人患者,先降流量、先降FiO2或同步降低三种策略均可选择,现有证据未显示某一策略更优。
- 需注意本研究样本量小,撤机成功率数值上的差异(94% vs 81% vs 77%)未达统计学显著性,不能据此推荐某一策略。
指南或共识出处
- Crit Care Med 发表的随机临床试验(SLOWH试验),原文未提供具体指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: This study evaluated the efficacy of different high-flow nasal cannula (HFNC) weaning protocols in critically ill adults.
DESIGN: This multicenter, randomized controlled trial was conducted from December 1, 2022, to August 31, 2024, based on the suggested protocol (SLOWH trial). Experts reviewed the trial between October 2, 2024, and April 15, 2025.
SETTING: Randomization was performed by a research coordinator using a sequence of random numbers generated by an independent statistician blinded to both researchers and participants.
PATIENTS: Adults (≥ 18 yr old) in the ICU who met the weaning criteria after receiving HFNC were included. Among 102 patients from three tertiary care hospitals, 15 were excluded.
INTERVENTIONS: The remaining patients were randomized into three intervention groups: flow reduction (FR) first, Fio2 reduction (OR) first, or simultaneous reduction (SR). The primary outcome was the HFNC weaning success rate, defined as successful transition to conventional oxygen therapy without the need for HFNC reapplication, noninvasive ventilation, or endotracheal intubation within 24 hours.
MEASUREMENTS AND MAIN RESULTS: A total of 87 adults completed the trial (FR, n = 31 [male, 52%]; OR, n = 26 [male, 77%]; SR, n = 30 [male, 53%]). The weaning success rates in the FR, OR, and SR groups were 94%, 81%, and 77%, respectively (p = 0.15). The median [interquartile range] weaning duration was 31.0 hours (29.0-45.8 hr), 29.5 hours (28.0-60.4 hr), and 29.5 hours (26.5-45.0 hr) in the FR, OR, and SR groups, respectively, with no statistically significant difference among groups (p = 0.87).
CONCLUSIONS: In this randomized trial, no statistically significant differences were observed among the three HFNC weaning strategies in terms of weaning success or duration.
参考来源
- Kim T, Kwack WG, Park S, et al. Weaning Strategies for High-Flow Nasal Cannula in Critically Ill Adults: A Randomized Clinical Trial. Crit Care Med. 2026. PMID: 42878628. doi:10.1097/CCM.0000000000007379
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。